Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors

• Conditions: Liver Cancer
• Interventions: Procedure: TACE

• Registration Number: NCT04739501
• Lead Sponsor: Assiut University

Brief Summary

Radiological response after trans arterial chemoembolization (TACE) is classified according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) to: complete response (CR) (disappearance of arterial enhancement), partial response (PR) ( at least a 30% decrease in the sum of diameters of viable enhancement), progressive disease (PD) (an increase of at least 20% in the sum of the diameters of viable enhancement, or appearance of new lesions), and stable disease (any cases that do not qualify for either partial response or progressive disease

Detailed Description

POST-TACE response of treatment for cases of hepatocellular cancer

Study Timeline

• Study First Submitted: 2020-03-25
• Study Start: 2020-12-01
• Status Verified: 2021-02
• Study First Submitted QC: 2021-02-03
• Last Update Submitted: 2021-02-03
• Study First Posted: 2021-02-04
• Last Update Posted: 2021-02-04
• Primary Completion: 2021-12-30
• Study Completion: 2022-03-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Clinical history and examination with special stress on symptoms and signs of chronic liver disease with or without evidence of hepatic decompensation e.g. the presence of ascites and with or without evidence of complications e.g. jaundice spider naevi, bleeding varices, ascites, and lower limb edema.

Laboratory findings in the form of raised bilirubin and liver enzymes, impaired coagulation profile, and/or low serum albumin.

Abdominal ultrasonography revealing liver cirrhosis (coarse echopattern, attenuated hepatic veins, irregular outlines, hypertrophy of caudate lobe and/or shrunken liver, presence of focal hepatic) and presence of splenomegaly, ascites, or portal vein thrombosis (PVT).

Exclusion Criteria

A patient who had surgical resection or liver transplantation Patients refuse to participate Hepatic focal lesion other than HCC

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
TACE in HCC group 1	TACE	the patient did undergo tace

Primary Outcome Measures

Name	Time	Method
Post_TACE hepatic cell failure	1 year	Frequency of liver cell failure in form of jaundice , coagulopathy and encephalopathy

Trial Locations

Locations (1)

Assiut; 🇪🇬 Assiut, Egypt